Glioma

Company licenses TransMID product to Nycomed

Published in Cancer Weekly, November 5th, 2002

KS Biomedix Holdings, plc, (KSB) has appointed Nycomed as the European licensee for its TransMID product in a licensing agreement worth up to $60 million.

TransMID is a biopharmaceutical product in development for the treatment of high grade glioma, a terminal brain cancer for which there is no known cure.

TransMID is based on the transferrin-mediated delivery of a modified diphtheria toxin, which is capable of selectively killing cancer cells. A completed phase II study conducted in leading neuro-oncology centers in the U.S.A. showed highly promising clinical response rates and an improvement in survival times in patients with recurrent brain...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry